{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:34:59Z","timestamp":1761896099632},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T00:00:00Z","timestamp":1437177600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s12185-015-1840-y","type":"journal-article","created":{"date-parts":[[2015,7,17]],"date-time":"2015-07-17T05:12:07Z","timestamp":1437109927000},"page":"342-348","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"102","author":[{"given":"Masatoshi","family":"Sakurai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Karigane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Tozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,7,18]]},"reference":[{"key":"1840_CR1","doi-asserted-by":"crossref","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. (2009) International randomized study of interferon vs STI571 (IRIS) 8\u00a0year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. In: Abstracts of 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 5\u20138 December 2009.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"1840_CR2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"NP Shah","year":"2010","unstructured":"Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PE, Enrico A, et al. Potent, transient inhibition of BCR-ABL with dasatinib 100\u00a0mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010;95:232\u201340.","journal-title":"Haematologica"},{"key":"1840_CR3","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 2011;117:1141\u20135.","journal-title":"Blood"},{"key":"1840_CR4","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1840_CR5","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"1840_CR6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-013-1470-1","volume":"99","author":"S Fujisawa","year":"2014","unstructured":"Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, Utsunomiya A, et al. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol. 2014;99:141\u201353.","journal-title":"Int J Hematol"},{"key":"1840_CR7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ajh.23691","volume":"89","author":"E Jabbour","year":"2014","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89:547\u201356.","journal-title":"Am J Hematol"},{"key":"1840_CR8","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bj\u00f6rkholm","year":"2011","unstructured":"Bj\u00f6rkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sj\u00f6berg J, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29:2514\u201320.","journal-title":"J Clin Oncol"},{"key":"1840_CR9","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1182\/blood.V66.6.1326.1326","volume":"66","author":"HM Kantarjian","year":"1985","unstructured":"Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, et al. Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 1985;66:1326\u201335.","journal-title":"Blood"},{"key":"1840_CR10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","volume":"63","author":"JE Sokal","year":"1984","unstructured":"Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia. Blood. 1984;63:789\u201399.","journal-title":"Blood"},{"key":"1840_CR11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","volume":"90","author":"J Hasford","year":"1998","unstructured":"Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst. 1998;90:850\u20138.","journal-title":"J Natl Cancer Inst"},{"key":"1840_CR12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3324\/haematol.10239","volume":"92","author":"G Rosti","year":"2007","unstructured":"Rosti G, Iacobucci I, Bassi S, Castagnetti F, Amabile M, Cilloni D, et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica. 2007;92:101\u20135.","journal-title":"Haematologica"},{"key":"1840_CR13","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1182\/blood-2010-12-324228","volume":"117","author":"G Gugliotta","year":"2011","unstructured":"Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, et al. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood. 2011;117:5591\u20139.","journal-title":"Blood"},{"key":"1840_CR14","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1200\/JCO.2010.30.5128","volume":"28","author":"DM Thomas","year":"2010","unstructured":"Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology: an emerging field. J Clin Oncol. 2010;28:4781\u20132.","journal-title":"J Clin Oncol"},{"key":"1840_CR15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/nrc2349","volume":"8","author":"A Bleyer","year":"2008","unstructured":"Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology., The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8:288\u201398.","journal-title":"Nat Rev Cancer"},{"key":"1840_CR16","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/jnci\/djj517","volume":"98","author":"C Schmidt","year":"2006","unstructured":"Schmidt C. Lack of progress in teen and young adult cancers concerns researchers, prompts study. J Natl Cancer Inst. 2006;98:1760\u20133.","journal-title":"J Natl Cancer Inst"},{"key":"1840_CR17","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/pbc.21462","volume":"50","author":"BH Pollock","year":"2008","unstructured":"Pollock BH, Birch JM. Registration and classification of adolescent and young adult cancer cases. Pediatr Blood Cancer. 2008;50:1090\u20133.","journal-title":"Pediatr Blood Cancer"},{"key":"1840_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1053\/j.seminoncol.2009.03.001","volume":"36","author":"CK Anders","year":"2009","unstructured":"Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36:237\u201349.","journal-title":"Semin Oncol"},{"key":"1840_CR19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.mph.0000157790.81329.47","volume":"27","author":"S Prakash","year":"2005","unstructured":"Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005;27:179\u201387.","journal-title":"J Pediatr Hematol Oncol"},{"key":"1840_CR20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJM200001133420216","volume":"342","author":"RV Datta","year":"2000","unstructured":"Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000;342:137\u20138.","journal-title":"N Engl J Med"},{"key":"1840_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/asheducation-2010.1.21","volume":"2010","author":"W Stock","year":"2010","unstructured":"Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2010;2010:21\u20139.","journal-title":"Hematol Am Soc Hematol Educ Program."},{"key":"1840_CR22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","volume":"97","author":"N Pemmaraju","year":"2012","unstructured":"Pemmaraju N, Kantarjian H, Shan J, Jabbour E, Quintas-Cardama A, Verstovsek S, et al. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012;97:1029\u201335.","journal-title":"Haematologica"},{"key":"1840_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-013-1937-4","volume":"93","author":"L Kalmanti","year":"2014","unstructured":"Kalmanti L, Saussele S, Lauseker M, Proetel U, M\u00fcller MC, Hanfstein B, et al. Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. Ann Hematol. 2014;93:71\u201380.","journal-title":"Ann Hematol"},{"key":"1840_CR24","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260\u201370.","journal-title":"N Engl J Med"},{"key":"1840_CR25","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251\u20139.","journal-title":"N Engl J Med"},{"key":"1840_CR26","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","volume":"17","author":"C Yoshida","year":"2012","unstructured":"Yoshida C, Fletcher L, Ohashi K, Wakita H, Kumagai T, Shiseki M, et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol. 2012;17:584\u20139.","journal-title":"Int J Clin Oncol."},{"key":"1840_CR27","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1840_CR28","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000363434","volume":"132","author":"N Pemmaraju","year":"2014","unstructured":"Pemmaraju N, Cortes J. Chronic myeloid leukemia in adolescents and young adults: patient characteristics, outcomes and review of the literature. Acta Haematol. 2014;132:298\u2013306.","journal-title":"Acta Haematol"},{"key":"1840_CR29","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","volume":"8","author":"JF Apperley","year":"2007","unstructured":"Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8:1018\u201329.","journal-title":"Lancet Oncol."},{"key":"1840_CR30","doi-asserted-by":"crossref","unstructured":"Bixby D, Talpaz M. Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance. Hematology Am Soc Hematol Educ Program. 2009; 461\u201376.","DOI":"10.1182\/asheducation-2009.1.461"},{"key":"1840_CR31","first-page":"231","volume":"15","author":"DM Geynisman","year":"2013","unstructured":"Geynisman DM, Wickersham KE. Adherence to targeted oral anticancer medications. Discov Med. 2013;15:231\u201341.","journal-title":"Discov Med."},{"key":"1840_CR32","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","volume":"28","author":"D Marin","year":"2010","unstructured":"Marin D, Bazeos A, Mahon FX, Eliasson L, Milojkovic D, Bua M, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28:2381\u20138.","journal-title":"J Clin Oncol"},{"key":"1840_CR33","doi-asserted-by":"crossref","unstructured":"Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). In: Abstracts of 2006 ASCO Annual Meeting, Atlanta, GA, 2\u20136 June 2006.","DOI":"10.1200\/jco.2006.24.18_suppl.6119"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-015-1840-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-015-1840-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T07:49:11Z","timestamp":1652860151000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-015-1840-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,18]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1840"],"URL":"https:\/\/doi.org\/10.1007\/s12185-015-1840-y","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,18]]}}}